
usd may pm et
summari compani distributor pharmaceut medical-surg suppli
relat product broad rang health care custom
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
mar-q revenu grew remark
yoy driven mainli yoy growth
revenu due strong
growth pharma distribut custom
month march surg
overal sale result
acceler demand medic sale
revenu yoy driven higher
product distribut sale particularli
ppe sale growth
howev cah segment saw
posit impact due
result increas demand mar-q trend
expect continu
yoy vs yoy earlier expect
delay cancel medic procedur
neg impact cah revenu
expect go beyond june-q
think rebound elect take time
moreov stagnant medic sale boost
surg ppe demand mar-q
view abl meet demand
exist stock deplet
estim fy ep flat
sinc complet share
repurchas program year assum
share repurchas
neutral share see limit
earn growth potenti amplifi
impact view product volum
steadili grow long term babi
expect mostli off-set lower
margin consolid custom gain
consolid health insur provid
pharmaci benefit manag on-going
trend saw combin aetna
express script
walgreen acquir much insur
also continu acquir region
provid trend pressur
oper margin view larger
custom abl negoti lower
target price fy jun ep
estim histor forward price-to-earnings
averag reflect view
signific neg impact due
start jun-q also think opioid
longer-than-anticip rebound elect
due sever gener price deflat
contract renew less favor term
despit near-term challeng due
healthcar distributor like see attract long-term
volum growth due age popul increas health
care util expand global middl class
gain access advanc medicin barrier entri
industri high three firm control
 drug distribut posit
off-set limit price power due consolid
larg custom opioid litig risk vertic
integr medic devic manufactur also bring
oper litig risk pure
distributor view
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug well specialti drug
oncolog infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut
center focus medic oper canada europ
asia oper margin gener higher medic fy saw medic oper margin
versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx extend june
market profil increas access health insur especi global middl class expand
well age popul develop nation posit demand driver health care distribut
long term view drug price inflat deflat howev one critic
factor drug distribut profit short term return wareh logist inventori
data servic larg distribut contract typic pay distributor negoti percentag health care
provid purchas order amount drug manufactur actual drug price negoti
drug manufactur downstream provid rise drug price therefor lead larger whole dollar
servic fee distributor inflat also help distributor tradit resal arrang
purchas bulk inventori manufactur resel downstream custom see profit
rise lower-cost exist inventori sold rise price
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market
share addit gener drug sourc joint ventur larg retail pharmaci
becom standard began collabor jv improv bargain power
gener manufactur set similar jv walgreen
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut view pharmaceut sale growth slow
last year slower growth tradit drug busi led distributor seek higher growth
margin relat busi specialti pharmaceut medic suppli
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop health care provid purchas medic
suppli medicin one vendor
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori cordi signific drag earn growth due oper
problem inventori write-down mount litig cost help fuel goodwil
impair medic segment fiscal
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
financi trend total revenu increas billion fy billion fy
repres three-year compound annual growth rate compound-annual-growth-rate revenu growth
boost sever acquisit period howev adjust pre-tax incom per share
account ad capit oper cost acquisit fell fy
fy three-year compound-annual-growth-rate neg drop incom driven steep
declin oper margin period leverag moder view fy adjust
oper incom cover net interest expens healthi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri posit
despit number headwind stem
pharmaceut distribut
rel well-plac current
environ expect major chang
demand prescript drug even
recess often necess
demand inelast view
hand see exponenti surg
demand person protect equip ppe
 global
number health care distributor
see distribut revenu bolster
growth prescript volum slowdown
brand drug patent expir
neg side expect profit margin
see continu pressur consolid
drug suppli chain focu mainli
drug distribut busi gener
sub-industri revenu
prescript drug demand continu
increas turn drive
greater volum handl distributor
driven view age
babi boomer prime util year
gain health-insur popul
accord latest censu data
age cohort grow five time fast
total popul expect age
drive long-term growth prescript drug
demand senior tend health care
need younger cohort
along rise prescript volum
distributor tend benefit higher
price brand drug gener
expect brand support favor
period low patent expir year
ahead data evaluatepharma indic
annual global drug sale risk expir
patent averag total
clear way substanti
amount lower-pr gener enter
market expir forecast drop
howev
posit brand drive
higher revenu distributor
typic collect percentag drug price
exchang manufactur
pharmaci exchang wareh
ship data track servic yet
longer term think brand drug price face
risk new regul politician
increasingli focus control voter drug
cost see outlook pharmaceut
immedi concern distributor
view grow scale player
drug suppli chain consolid drug
maker upstream well pbm manag
care firm provid downstream
on-going
consolid increas negoti power
supplier custom distributor
limit abil improv oper margin
posit correl recent
year health
distributor index tend move
direct year date april
health distributor index
decreas compar
decreas experienc broader
healthcar sector decreas
overal index
health distributor index
increas line rise
healthcar sector rise
 index
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
nation opioid case key bellweth trial opioid epidem
schedul begin monday intent presid judg bring
side comprehens settlement resolv relat case nationwid
trial approach see flurri report settlement
negoti includ news week big drug distributor
 propos cap total liabil pay year
produc teva offer settlement worth
respect earli know coalit state attorney lead
negoti behalf plaintiff stand offer see
defend willing settl posit news opioid litig uncertainti
gener cost defend market valu via neg sentiment
like cost settl view move toward settlement even costli
one defend see share rise uncertainti allevi /colin scarola
et cfra maintain hold opinion share inc
lower target fy jun ep
estim histor forward price-to-earnings averag due margin contract
lower fy ep estim initi fy
jun-q ep vs beat consensu jun-q revenu grew
yoy led yoy growth pharmaceut revenu pharmaceut
also grew oper profit total yoy
encourag sign investor end straight quarter
oper profit declin stretch back gener price
deflat continu headwind
off-set strong demand specialti drug medic oper profit
fell yoy jun-q howev driven rise cost relat
cardin brand product strategi think averag valuat
warrant demonstr invest medic segment
deliv adequ return capit /colin scarola
analyst research note compani news
et cfra keep hold opinion share inc
cut target ep estim
cah histor forward price-to-earnings averag reflect view
neg revenu impact due start jun-q cut fy ep
estim expect jun-q advers affect
full quarter decreas number elect procedur cut fy
ep forecast mar-q ep vs
estim consensu mar-q revenu grew remark
yoy estim drive stock price morn
segment saw posit impact due result increas
demand stockpil growth led
yoy due stronger pharma distribut revenu surg overal march
sale result acceler demand medic sale
revenu yoy due growth product distribut well
cardin /sel hardi
et cfra keep hold opinion share inc
rais target higher ep
estim reflect view share gain potenti follow better
expect dec-q result rais fy guidanc increas fy ep
estim rais fy ep forecast
dec-q ep vs beat consensu dec-q total
sale yoy pharma provid total sale yoy
medic segment flat yoy posit perform pharma driven
strength gener drug specialti solut offset advers impact
pharma distribut custom contract renew medic segment
flat perform mainli relat declin product distribut
oper earn decreas yoy dec-q due
one-off charg relat surgic gown recal due issu
steril one supplier china shift product unapprov
et cfra keep buy opinion share mckesson corpor
saw share test high yesterday fy
guidanc updat favor sentiment follow ceo
present major healthcar confer rais outlook fy
adj ep analyst estim includ stood
versu earlier follow releas
lift fy ep estim confid
deliv improv fy guidanc maintain fy fy
estim differ note news broke oklahoma ag file
lawsuit countri largest opioid distributor
corp oversuppli
opioid oklahoma although view news increas legal risk
three compani investor respons mute three
close day /sel hardi
pm et cfra maintain hold opinion share inc
lift target fy jun ep
estim -- histor forward price-to-earnings averag due margin
contract maintain fy ep estim drop fy
sep-q ep vs beat consensu medic oper
profit total grew impress yoy long-term effici
initi gain traction pharmaceut oper profit fell
yoy howev neg impact renew largest custom
less profit term expect pharma earn declin even faster
yoy fy contrast sharpli peer whose oper
earn see grow next year attribut diverg
lower market share rapidli grow specialti drug
immuno-oncolog encourag improv medic think
below-p valuat warrant given primari pharma segment
declin peer grow /colin scarola
et cfra see investor sentiment improv defend
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
